Thus, we aimed to assess the value of AP, CEA, LDH and NSE serum levels prior to PSMA-RGS in oligorecurrent PCa as potential tools for guiding treatment strategy and patient selection. This evidence concerns the gene FOLH1 and posterior cortical atrophy.